Early-onset schizophrenia

Summary

Early-onset schizophrenia (MONDO:0019939) is a disease and 4 clinical trials. Top therapeutic interventions include olanzapine. A subtype of schizophrenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	early-onset schizophrenia
Mondo ID	MONDO:0019939
Orphanet	96369
UMLS	C1656427
MedGen	1800824
GARD	0019352
Is cancer (heuristic)	no

Disease family

This is a subtype of schizophrenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › schizophrenia › early-onset schizophrenia

Related subtypes (17): paranoid schizophrenia, treatment-refractory schizophrenia, schizophrenia 1, schizophrenia 3, schizophrenia 5, schizophrenia 7, schizophrenia 8, schizophrenia 2, schizophrenia 10, schizophrenia 11, schizophrenia 12, schizophrenia 15, schizophrenia 16, chromosome 2p16.3 deletion syndrome, schizophrenia 19, schizophrenia 17, childhood-onset schizophrenia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02435654	PHASE4	COMPLETED	5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
NCT03068793	Not specified	COMPLETED	Reward Processing in Mental Illness
NCT05405946	Not specified	UNKNOWN	Computerized Cognitive Remediation Therapy in Adolescents With a First Psychotic Episode
NCT05577338	Not specified	COMPLETED	ToM Psychotherapy and Brain Networks in EOS

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OLANZAPINE	4	1